Last updated: May 28, 2026

Application No. 18/555,640

SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT

Non-Final OA

Filed

Oct 16, 2023

Priority

Apr 16, 2021 — provisional 63/176,135 +1 more

Examiner

OH, TAYLOR V

Art Unit

1625

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Merck Sharp & Dohme LLC

OA Round

1 (Non-Final)

Interview Optional

— +15.4% interview lift. Examiner has a relatively high allowance rate (81%); +15.4% interview lift. A written response may suffice.

Based on 1754 resolved cases, 2023–2026

Examiner Intelligence

OH, TAYLOR V View full profile →

Grants 81% — above average

Career Allowance Rate

1423 granted / 1754 resolved

+21.1% vs TC avg

Strong +15% interview lift

Without

With

+15.4%

Interview Lift

resolved cases with interview

Typical timeline

2y 3m

Avg Prosecution

23 currently pending

Career history

1782

Total Applications

across all art units

Statute-Specific Performance

§101

0.7%

-39.3% vs TC avg

§103

61.6%

+21.6% vs TC avg

§102

15.5%

-24.5% vs TC avg

§112

16.8%

-23.2% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1754 resolved cases

Prosecution Timeline

Oct 16, 2023

Application Filed

Feb 11, 2026

Non-Final Rejection mailed

May 11, 2026

Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

17/919,660

Patent 12630503

METHOD FOR PRODUCING BENZOPYRANONE COMPOUND AND NOVEL INTERMEDIATE USED THEREIN

3y 7m to grant Granted May 19, 2026

18/131,695

Patent 12629350

TRANSTHYRETIN TETRAMER STABILIZING AGENT, AND PREVENTING AGENT OR PROGRESSION SUPPRESSING AGENT FOR TRANSTHYRETIN AMYLOIDOSIS

3y 1m to grant Granted May 19, 2026

18/041,394

Patent 12624013

PURIFICATION OF 2,5-FURANDICARBOXYLIC ACID, DIMETHYL ESTER AND OTHER ESTERIFIED PRODUCTS

3y 3m to grant Granted May 12, 2026

18/269,830

Patent 12612391

CROMOLYN DERIVATIVES AND USES THEREOF

2y 10m to grant Granted Apr 28, 2026

18/039,236

Patent 12599614

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF MICROBIAL INFECTIOUS DISEASES AND ASSOCIATED INFLAMMATORY DISORDERS AND FOR THE TREATMENT AND PROPHYLAXIS OF AGING AND ASSOCIATED DISEASES

2y 10m to grant Granted Apr 14, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

81%

Grant Probability

96%

With Interview (+15.4%)

2y 3m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 1754 resolved cases by this examiner. Grant probability derived from career allowance rate.